Analysis Of The Effect Of Age On Medication Adherence With Oral Antidiabetes And Oral Antihypertension Drugs Using Pill Count Method

2021 ◽  
Vol 6 (2) ◽  
pp. 63-68
Author(s):  
Ninik Mas Ulfa ◽  
Rizky Darmawan
Keyword(s):  
Elderly Patients ◽  
Patient Compliance ◽  
Antihypertensive Drugs ◽  
Pill Count ◽  
Oral Antidiabetic Drugs ◽  
Chi Square ◽  
Oral Antidiabetic ◽  
Count Method ◽  
The Many ◽  
Effect Of Age

Compliance with taking medication is a problematic patients who get polypharmacy prescribing, this is because of the many drugs that must be consumed. As a result of the consumption of many drugs that cause sufferers of degenerative diseases are not compliant to take medication and health awareness decreases. This is not only experienced in elderly and geriatric patients but in adulthood also experience non-compliance with taking medication due to the many activities, lazy to take medication and also forget. This study was conducted to analyze the effect of age on adherence to taking oral antidiabetic drugs and oral antihypertensive drugs using the pill count method at the Regional Hospital of South Surabaya. The Pill Count method was chosen in this study with the aim of analyzing patient compliance in taking medication by calculating the remaining drug based on the rules of use and dosage when the patient returns to control. In addition, this study also aims to determine the effect of age on patient compliance in taking oral antidiabetic drugs and oral antihypertensive drugs. This research is descriptive observational with prospective data collection. Data analysis used descriptive and continued with statistical analysis using Chi-Square. The results of this study that adherence to take medication for elderly patients who received oral antidiabetic drug therapy obtained as much as 96.7% and 90% in adult patients. Compliance to oral antihypertension drugs in adult patients are  90% and 83.3% in elderly patients. Age does not effect compliance patients with Chi-Square analysis with p value = 0,301 and 0,448 > 0.05.

Pengaruh Penggunaan Obat Antihipertensi Terhadap Sindroma Mata Kering di Surabaya

2020 ◽  
Vol 17 (2) ◽  
pp. 159
Author(s):  
WISNU TRI PAMUNGKAS ◽  
INDIRA RA ◽  
IRMA ANDRIANI PASARIBU
Keyword(s):  
Public Health ◽  
Health Center ◽  
Dry Eye ◽  
Channel Blocker ◽  
Antihypertensive Drugs ◽  
Descriptive Analysis ◽  
Dry Eye Syndrome ◽  
Chi Square ◽  
Cross Sectional ◽  
Public Health Center

<p><strong>Abstrak</strong></p><p><strong>Latar Belakang : </strong>Prevalensi Hipertensi di Indonesia semakin meningkat mencapai 25,8% pada penduduk berusia 18 tahun keatas.  Amlodipin merupakan salah satu pilihan obat untuk terapi Hipertensi yang termasuk golongan Calsium Channel Blocker (CCB). Penggunaan obat antihipertensi sendiri merupakan salah satu faktor risiko yang menyebabkan sindroma mata kering.</p><p><strong>Tujuan : </strong>Penelitian ini bertujuan untuk mengetahui pengaruh penggunaan obat antihipertensi terhadap sindroma mata kering pada penderita Hipertensi di wilayah kerja Puskesmas Jagir kota Surabaya.</p><p><strong>Metode penelitian : </strong>Penelitian ini adalah penelitian observasional analitik dengan metode cross-sectional. Subyek pada penelitian ini adalah 48 responden yang didapatkan dibagi kedalam 2 kelompok yakni, kelompok minum obat antihipertensi &gt;6 bulan dan tidak minum obat. Dilakukan pengisian kuesioner DEQ-5 dan pemeriksaan schirmer I.</p><p><strong>Hasil penelitian : </strong>Analisa deskriptif dari tes schirmer I frekuensi sindroma mata kering lebih tinggi pada responden yang mengkonsumsi obat antihipertensi dari pada responden yang tidak minum obat antihipertensi. Hasil analisa statistik menggunakan uji chi-square signifikansinya yaitu sebesar &lt;0,001 atau dapat dikatakan bahwa p&lt;α (0,05), menunjukkan ada pengaruh pemberian obat antihipertensi terhadap sindroma mata kering yang berdasarkan tes Schirmer pada pasien Hipertensi di wilayah kerja puskesmas Jagir  kota Surabaya.</p><p><strong>Simpulan : </strong>Penggunaan obat antihipertensi berpengaruh terhadap sindroma mata kering pada penderita hipertensi di wilayah kerja Puskesmas Jagir kota Surabaya</p><p><strong>Kata Kunci : </strong>Sindroma mata kering, obat antihipertensi, hipertensi</p><p><strong> </strong></p><p><strong>Abstract</strong></p><p><strong>Background: </strong>Hypertension prevalence in Indonesia is increasing to reach 25.8% in the population aged 18 years and over. Amlodipine is one of the drugs for hypertension therapy which is included in the Calcium Channel Blocker (CCB) class. The use of antihypertensive medication itself is one of the risk factors that cause dry eye syndrome.</p><p><strong>Purpose</strong>: This study aims to determine the effect of the use of antihypertensive drugs on dry eye syndrome in patients with hypertension at Jagir Public Health Center in Surabaya working area.</p><p><strong>Methods:</strong> This study was an observational analytic study with a cross-sectional method. The subjects in this study were 48 respondents found divided into 2 groups namely, the group taking antihypertensive drugs&gt; 6 months and not taking medication. The DEQ-5 questionnaire was completed and Schirmer I was examined.</p><p><strong>Results:</strong> Descriptive analysis of the Schirmer I test for the frequency of dry eye syndrome was higher in respondents who took antihypertensive drugs than those who did not take antihypertensive drugs. The results of statistical analysis using the chi-square test of significance that is equal to &lt;0.001 or it can be said that p &lt;α (0.05), indicates there is an effect of antihypertensive drug administration on dry eye syndrome based on the Schirmer test in hypertension patients at Jagir Public Health Center in Surabaya..</p><p><strong>Conclusion:</strong> The use of antihypertensive drugs has an effect on dry eye syndrome in patients with hypertension at the Jagir Public Health Center in Surabaya</p><strong>Keywords:</strong> Dry eye syndrome, antihypertensive drugs, hypertension

The Effect of Cognitive Remediation Therapy on Social Skills in Institutionalized Elderly Patients with Schizophrenia

2017 ◽  
Vol 12 (3) ◽  
pp. 182-186 ◽  
Author(s):  
Fatemeh Mohammadi ◽  
Yadollah Abolfathi Momtaz ◽  
Seyedeh Ameneh Motalebi ◽  
Shahnaz Boosepasi
Keyword(s):  
Social Skills ◽  
Elderly Patients ◽  
Behavioral Problems ◽  
Psychiatric Patients ◽  
Intervention Group ◽  
Cognitive Remediation ◽  
Control Group ◽  
Cognitive Remediation Therapy ◽  
Chi Square ◽  
Institutionalized Elderly

Background: There are limited scientific investigations on cognitive remediation in elderly patients with schizophrenia. The present study was aimed to examine the efficacy of cognitive remediation therapy on social skills in institutionalized elderly patients with schizophrenia. Methods: The study employed a randomized clinical trial. A total of 60 institutionalized elderly patients with schizophrenia from Razi Psychiatric Hospital, Tehran were selected and randomly allocated into two equal groups (control and intervention). The intervention group attended to cognitive remediation therapy for 8 weeks. The Evaluation of Living Skills Scale for psychiatric patients was used for data collection. The Chi Square, independent and paired t-tests using SPSS, version 22, were employed to analyze the data. Results: The mean age of 60 elderly patients participated in the study was 65.25 &#177; 4.19 years. No significant differences were found between two groups at baseline. However, independent t-tests showed significant differences between the intervention and the control group in social skills after implementation of intervention. Additionally, the results of paired t-tests revealed significant improvements in intervention group on communication skills (t=5.50, p<0.001), behavioral problems with others (t=5.44, p<0.001), and self-care (t=4.70, p<0.001). No significant differences were observed from pretest to post test in control group. Conclusion: The results of the present study may support the efficacy of cognitive remediation therapy on social skills of elderly patients with schizophrenia.

Transcending the Cutaneous Barrier Through Nanocarrier Exploration for Passive Delivery of Anti-hypertensive Drugs: A Critical Review

2020 ◽  
Vol 14 (3) ◽  
pp. 193-209
Author(s):  
Lalit Kumar ◽  
Puneet Utreja
Keyword(s):  
Patient Compliance ◽  
Transdermal Delivery ◽  
Antihypertensive Drugs ◽  
Skin Barrier ◽  
Oral Route ◽  
Term Treatment ◽  
New Approaches ◽  
Long Term Treatment ◽  
First Pass ◽  
Transdermal Route

Background: Hypertension comes under the category of chronic disease, which requires long term treatment. Hypertension is usually treated by oral administration of various therapeutic agents. There are several limitations of the oral route, making pharmaceutical scientists to discover an alternative route for drug delivery. Methods: The transdermal route may be a better alternative as it shows various advantages like lack of first-pass effect and high patient compliance. The skin may act as a primary barrier for the transdermal delivery of anti-hypertensive drugs; therefore, new approaches are required to cross this barrier. Nanocarrier systems come under these new approaches to cross the skin barrier. Various nanocarrier systems explored for transdermal delivery of antihypertensive drugs are liposomes, elastic liposomes, ethosomes, transethosomes, oleic acid vesicles, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions/microemulsions, and carbon nanotubes. Results: This review summarizes the potential of advanced nanocarrier systems for effective management of hypertension following the transdermal route. The entire literature search regarding the utility of nanocarrier systems in transdermal delivery of antihypertensive drugs was done by using Pubmed and Google Scholar. Conclusion: Nanocarrier systems are capable of reducing various drawbacks of conventional formulations of antihypertensive drugs like excessive first-pass effects, high dosing frequency, and toxicity promoting high patient compliance. However, the clinical efficacy determination of such nanocarrier systems is still a challenge and it will govern their presence in the global pharmaceutical market.

scholarly journals Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study

Pituitary ◽  
2021 ◽  
Author(s):  
Susan L. Samson ◽  
Feng Gu ◽  
Ulla Feldt-Rasmussen ◽  
Shaoling Zhang ◽  
Yerong Yu ◽  
...  
Keyword(s):  
Cushing’S Disease ◽  
Rescue Therapy ◽  
Antidiabetic Drugs ◽  
Cushing's Disease ◽  
Oral Antidiabetic Drugs ◽  
Open Label ◽  
Oral Antidiabetic ◽  
Open Label Phase ◽  
Core Phase ◽  
Phase Iv

Abstract Purpose Pasireotide is an effective treatment for acromegaly and Cushing’s disease, although treatment-emergent hyperglycemia can occur. The objective of this study was to assess incretin-based therapy versus insulin for managing pasireotide-associated hyperglycemia uncontrolled by metformin/other permitted oral antidiabetic drugs. Methods Multicenter, randomized, open-label, Phase IV study comprising a core phase (≤ 16-week pre-randomization period followed by 16-week randomized treatment period) and optional extension (ClinicalTrials.gov ID: NCT02060383). Adults with acromegaly (n = 190) or Cushing’s disease (n = 59) received long-acting (starting 40 mg IM/28 days) or subcutaneous pasireotide (starting 600 µg bid), respectively. Patients with increased fasting plasma glucose (≥ 126 mg/dL on three consecutive days) during the 16-week pre-randomization period despite metformin/other oral antidiabetic drugs were randomized 1:1 to open-label incretin-based therapy (sitagliptin followed by liraglutide) or insulin for another 16 weeks. The primary objective was to evaluate the difference in mean change in HbA1c from randomization to end of core phase between incretin-based therapy and insulin treatment arms. Results Eighty-one (32.5%) patients were randomized to incretin-based therapy (n = 38 received sitagliptin, n = 28 subsequently switched to liraglutide; n = 12 received insulin as rescue therapy) or insulin (n = 43). Adjusted mean change in HbA1c between treatment arms was – 0.28% (95% CI – 0.63, 0.08) in favor of incretin-based therapy. The most common AE other than hyperglycemia was diarrhea (incretin-based therapy, 28.9%; insulin, 30.2%). Forty-six (18.5%) patients were managed on metformin (n = 43)/other OAD (n = 3), 103 (41.4%) patients did not require any oral antidiabetic drugs and 19 patients (7.6%) were receiving insulin at baseline and were not randomized. Conclusion Many patients receiving pasireotide do not develop hyperglycemia requiring oral antidiabetic drugs. Metformin is an effective initial treatment, followed by incretin-based therapy if needed. ClinicalTrials.gov ID: NCT02060383.

Hardy-Weinberg Testing for Continuous Data

Genetics ◽  
1997 ◽  
Vol 147 (4) ◽  
pp. 1965-1975
Author(s):  
Lauren M McIntyre ◽  
B S Weir
Keyword(s):  
Intraclass Correlation ◽  
Kernel Density ◽  
Variable Number ◽  
Continuous Data ◽  
Test Statistic ◽  
Test Procedures ◽  
Chi Square ◽  
Exact Test ◽  
Chi Square Test ◽  
The Many

Abstract Estimation of allelic and genotypic distributions for continuous data using kernel density estimation is discussed and illustrated for some variable number of tandem repeat data. These kernel density estimates provide a useful representation of data when only some of the many variants at a locus are present in a sample. Two Hardy-Weinberg test procedures are introduced for continuous data: a continuous chi-square test with test statistic TCCS and a test based on Hellinger's distance with test statistic TCCS. Simulations are used to compare the powers of these tests to each other and to the powers of a test of intraclass correlation TIC, as well as to the power of Fisher's exact test TFET applied to discretized data. Results indicate that the power of TCCS is better than that of THD but neither is as powerful as TFET. The intraclass correlation test does not perform as well as the other tests examined in this article.

Sign in / Sign up

Export Citation Format

Share Document